MESOTHELIOMA

This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with advanced pleural mesothelioma live longer. The trial included 214 adults whose cancer could not be removed by surgery. Participants received either the drug combo or a st…

This early-stage study tested a new drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced cancers like lung cancer, melanoma, or head and neck cancer that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal…

This study tested a way to deliver high doses of three chemotherapy drugs directly to the tumor through an artery in 34 adults with malignant pleural mesothelioma that could not be removed by surgery. The goal was to see if this approach could control the disease and improve surv…

This study allowed people with certain cancers who had already benefited from the drug tazemetostat in earlier studies to keep receiving it. The main goal was to track long-term safety and side effects. Participants had already shown clinical benefit and continued treatment under…

This early-stage study tested a combination of a radioactive drug (177Lu-DOTA-TATE) and a targeted pill (olaparib) in 18 adults with certain tumors that have a specific marker. The goal was to find the safest dose and understand side effects. This approach aims to make tumor cell…

This study looked at whether a new biomarker called 'mass response' can help predict how well cancer treatments will work. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or biopsies. The goal was to see if this biomarker could guide ther…